1.Primary lymphoma of the eye.
Jee Sook HAHN ; Chang Ok SUH ; Sang Yeul LEE ; Woo Ick YANG
Yonsei Medical Journal 1998;39(3):196-201
Lymphomas in the eye tend to be localized and to have a better prognosis. We reviewed the clinical presentation, treatment outcome and complications of primary lymphomas of the eye at a single institute focusing on the clinical significance of adequate staging and the prognostic value of pathological subtypes. Twenty-four patients with lymphoproliferative lesion of the eye were treated and followed up. The orbit was the most commonly involved site. Twenty-one patients had unilateral diseases and three patients had bilateral. Histological findings revealed 22 malignant lymphomas, one inflammatory pseudotumor and one atypical lymphoid hyperplasia. Using the NCI Working Formulation, most of the malignant lymphomas were primarily low grade: diffuse small lymphocytic, 15; diffuse small cleaved three; diffuse large cell, three; and diffuse mixed, one. The stages of lymphoma were IAE in 21 patients, IBE in one patient, and IIAE in two patients. Twenty-five of the 27 treated eyes remained disease-free during the median follow-up period of 16 months. Nineteen patients received radiotherapy, five patients received chemo-radiotherapy and one patient received only surgical excision. Two patients relapsed outside the treated field. None of the patients complained of severe dry eye syndrome or cataract formation. In conclusion, after complete staging work-up, locally-confined low grade orbital lymphomas can be up to 90% controlled with radiotherapy alone. By contrast, combined treatment is advised in patients with intermediate and high grade lesions.
Adolescence
;
Adult
;
Aged
;
Antineoplastic Agents, Combined/therapeutic use
;
Combined Modality Therapy
;
Eye Neoplasms/radiotherapy*
;
Eye Neoplasms/pathology*
;
Eye Neoplasms/drug therapy
;
Female
;
Human
;
Lymphoma/radiotherapy*
;
Lymphoma/pathology*
;
Lymphoma/drug therapy
;
Male
;
Middle Age
;
Neoplasm Staging
;
Survival Analysis
2.Chemosensitization to adriamycin by cyclosporin A and verapamil in human retinoblastoma cell lines.
Tai Won LEE ; Sung Wook YANG ; Chang Min KIM ; Weon Seon HONG ; Dong Ho YOUN
Journal of Korean Medical Science 1993;8(2):104-109
The chemosensitizing effects of cyclosporin A and verapamil on the cytotoxicity of adriamycin were investigated using MTT assay against two human retinoblastoma cell lines, Y79 and WERI-Rb-1. Y79 and WERI-Rb-1 were totally resistant to doses up to 5.0 micrograms/ml of verapamil. Cyclosporin A inhibited the survival of Y79 and WERI-Rb-1 dose-dependently, however, the maximum inhibition at the highest concentration tested (5.0 micrograms/ml) was less than 50% (% survival at 5.0 micrograms/ml of cyclosporin A: 65.6% and 66.9% in Y79 and WERI-Rb-1, respectively). Combination of cyclosporin A and verapamil did not further inhibit the survival of Y79 and WERI-Rb-1 compared with cyclosporin A alone. Adramycin inhibited the survival of Y79 and WERI-Rb-1 dose-dependently. The chemosensitizing effects of cyclosporin A and verapamil on the cytotoxicity of adriamycin were evaluated in terms of sensitizing index (SI: the ratio of IC50 to adriamycin alone to IC50 to adriamycin in the presence of cyclosporin A and/or verapamil). Cyclosporin A significantly enhanced SI and the addition of verapamil enhanced SI further: SI values at 5.0 micrograms/ml of cyclosporin A, 5.0 micrograms/ml of cyclosporin A plus 1.5 micrograms/ml of cyclosporin A plus 1.5 micrograms/ml of verapamil, 5.0 micrograms/ml of cyclosporin A plus 3.0 micrograms/ml of verapamil were 2.0, 2.6 and 2.8 in Y79 and 2.6, 5.8 and 9.7 in WERI-Rb-1, respectively. These results suggest that cyclosporin A and verapamil are promising chemosensitizers to adriamycin in the treatment of retinoblastoma.
Cell Survival/drug effects
;
Cyclosporine/*pharmacology
;
Doxorubicin/*pharmacology
;
Eye Neoplasms/drug therapy/*pathology
;
Humans
;
Retinoblastoma/drug therapy/*pathology
;
Tumor Cells, Cultured
;
Verapamil/*pharmacology
3.The Clinical Characteristics and Treatment Results of Ocular Adnexal Lymphoma.
Jung Min WOO ; Chien Kue TANG ; Mee Sook RHO ; Jin Hwa LEE ; Hyuk Chan KWON ; Hee Bae AHN
Korean Journal of Ophthalmology 2006;20(1):7-12
PURPOSE: To assess the clinical pattern, the histopathological findings, the response to treatments, the recurrence pattern and the prognosis of malignant lymphoma in the ocular adnexa. METHODS: This study was performed on 22 total eyes from 17 patients who were diagnosed with ocular adnexal malignant lymphoma. We retrospectively analyzed the medical records for patient information including the histological classification based on age, the gender of each patient, the symptoms and signs at the initial diagnosis, the presence of binocular invasion, the findings of the surgical biopsy, the clinical stage of each patient's tumor, and the treatment methods used and their effectiveness. The mean follow-up period was 24.8 months. RESULTS: The mean age of patients studied was 46.8 years old. Six females and 11 males were included in the study. Fifteen cases consisting of 20 total eyes represented extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT). Five of seven patients (71.4%) whose lymphoma occurred within the conjunctiva relapsed after irradiation or chemotherapy, and four of the relapsed patients were salvaged with further therapy. CONCLUSIONS: Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT) constituted 88.2% of all lymphomas involving the ocular adnexa. Lymphoma in the ocular adnexa responded well to conventional treatment, but the recurrence rate of lymphoma in the conjunctiva was significantly high.
Treatment Outcome
;
Retrospective Studies
;
Neoplasm Recurrence, Local
;
Middle Aged
;
Male
;
Lymphoma, Mucosa-Associated Lymphoid Tissue/drug therapy/*pathology/radiotherapy/surgery/*therapy
;
Humans
;
Follow-Up Studies
;
Female
;
Eye Neoplasms/drug therapy/*pathology/radiotherapy/surgery/*therapy
;
Combined Modality Therapy
;
Biopsy
;
Aged, 80 and over
;
Aged
;
Adult